Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 292

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 292
---

    termination of collaborations;

    ●
    regulatory or legal
    developments in the United States and other countries;

    ●
    developments or
    disputes concerning patent applications, issued patents or other proprietary rights;

    ●
    the recruitment
    or departure of key personnel;

    ●
    the level of expenses
    related to any of our current or future compounds or clinical development programs;

    ●
    the results of our
    efforts to discover, develop, acquire or in-license additional new compounds;

    ●
    actual or anticipated
    changes in estimates as to financial results, development timelines or recommendations by securities analysts;

    ●
    our inability to
    obtain or delays in obtaining adequate product supply for any approved product or inability to do so at acceptable prices;

    ●
    disputes or other
    developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection
    for our technologies;

    ●
    significant lawsuits,
    including patent or stockholder litigation;

    ●
    variations in our
    financial results or those of companies that are perceived to be similar to us;

    ●
    changes in the structure
    of healthcare payment systems;

    ●
    market conditions
    in the pharmaceutical and biotechnology sectors;

    ●
    general economic,
    industry and market conditions; and

    ●
    the other factors
    described in this “Risk Factors” section.

60 

The
stock markets have experienced extreme volatility in recent years that has been unrelated to operating performance. These broad
market fluctuations may adversely affect the trading price of our securities. In the past, following periods of volatility in
the market price of a company’s securities, class action litigation has often been instituted against the affected company.
Any litigation of this type brought against us could result in substantial costs and a diversion of our management’s attention
and resources, which would harm our business, results of operations, financial condition and cash flows.

We
have broad discretion in the use of our cash and may not use them effectively.

Our
management will have broad discretion in the application of our cash and could spend the proceeds in ways that do not improve
our results of operations or enhance the value of our Common Stock. The failure by our management to apply these funds effectively
could result in financial losses that could have a material adverse effect on our business, cause the price of our Common Stock
to decline and delay the development of CC8464, CT2000 and